Oriola-KD Corporation's Interim Report for 1 January - 30

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oriola-KD Corporation's Interim Report for 1 January - 30 June 2016

Oriola-KD Corporation Stock Exchange Release 19 July 2016 at 8.30 a.m.

Oriola-KD Corporation's Interim Report for 1 January - 30 June 2016

Financial performance April-June 2016

  • Invoicing increased by 7.8 per cent to EUR 887.3 (823.1) million
  • Net sales increased by 0.8 per cent to EUR 420.2 (417.1) million
  • Adjusted EBITDA increased by 3.5 per cent to EUR 21.3 (20.6) million
  • Adjusted operating profit was EUR 14.8 (14.9) million
  • Profit for the period totalled EUR 9.7 (10.9) million and earnings per share were EUR 0.05 (0.06)

Financial performance January-June 2016

  • Invoicing increased by 6.5 per cent to EUR 1,721.7 (1,616.5) million
  • Net sales decreased by 0.8 per cent to EUR 821.5 (828.4) million
  • Adjusted EBITDA increased by 5.4 per cent to EUR 41.4 (39.3) million
  • Adjusted operating profit was EUR 28.7 (28.1) million
  • Profit for the period totalled EUR 19.8 (18.3) million and earnings per share were EUR 0.11 (0.11)

Outlook for 2016

Oriola-KD estimates its full-year net sales to remain at the 2015 level on constant currency basis. Adjusted operating profit is estimated to remain at 2015 level or to increase, on a constant currency basis. Full-year net sales in 2015 were EUR 1,626.3 million and adjusted operating profit was EUR 60.8 million.

President and CEO Eero Hautaniemi:

The first half of 2016 went in line with our expectations. In Consumer business our growth continued to be slightly below market, but the sales mix developed favorably supporting the profitability. In Q2 we succeeded well with the sales of seasonal products. In Services business volumes continued to be at good level and we completed the closure of Oulu distribution center as planned. Healthcare business was somewhat burdened with start-up costs related to hospital and veterinarian businesses but dose dispensing business performed according to plans. July 18 announced acquisition of Pharmaservice Oy in Finland makes Oriola-KD a leading dose dispensing company in our main markets Sweden and Finland and is an important step in our way to build the third business area, Healthcare.

Impact of new ESMA guidelines

New ESMA (European Securities and Markets Authority) guidelines on Alternative Performance Measures (APMs) are effective for the financial year 2016. Oriola-KD presents APMs to reflect the underlying business performance and to enhance comparability between financial periods. APMs should not be considered as a substitute for measures of performance in accordance with the IFRS. As of Q1 2016, Oriola-KD relabels the previously referenced "excluding non-recurring items" with "adjusted". Reporting segments' operating profit is reported excluding adjustment items. In addition Oriola-KD uses "invoicing" as the measure to describe the business volume.The reconciliation of the alternative performance measurements to performance measurments defined by IFRS are presented at the end of this interim report.

Key figures 2016 2015 Change 2016 2015 Change 2015
EUR million 4-6 4-6 1) % 1-6 1-6 1) % 1-12
Invoicing 887.3 823.1 7.8 1,721.7 1,616.5 6.5 3,262.2
Net sales 420.2 417.1 0.8 821.5 828.4 -0.8 1,626.3
Adjusted EBITDA 21.3 20.6 3.5 41.4 39.3 5.4 83.4
Adjusted EBITDA % 5.1 4.9   5.0 4.7   5.1
Adjusted operating profit 2) 14.8 14.9 -1.1 28.7 28.1 2.3 60.8
Operating profit 14.0 15.2 -7.8 27.9 26.9 3.8 62.6
Adjusted operating profit % 3.5 3.6   3.5 3.4   3.7
Operating profit % 3.3 3.6   3.4 3.2   3.8
Profit for the period 9.7 10.9 -10.8 19.8 18.3 7.9 44.5
Earnings per share, EUR 0.05 0.06 -14.3 0.11 0.11 1.2 0.25
Net cash flow from operating activities 21.7 25.6   -5.1 38.9   85.6
Gross investments, EUR million       35.5 8.1   20.4
               
Total assets       934.1 911.9   946.9
Net interest-bearing debt       66.2 42.0   6.6
Gearing, %       35.8 25.9   3.4
Net debt / 12-month EBITDA       0.8 0.5   0.1
               
Equity per share, EUR       1.02 0.90   1.07
Equity ratio, %       20.6 18.4   21.1
Return on equity (ROE), %       21.9 28.5   29.1
Return on capital employed (ROCE), %       17.6 18.7   19.9
Average number of shares, 1000 pcs 3)       181,389 169,984   177,502
               
Average number of personnel       2,419 2,299   2,327
Number of personnel at the end of the period       2,465 2,312   2,353
               
1) Equity-related key figures restated as a result of correction of an error relating to previous financial periods. Correction was made in 2015 Financial Statements. 2) Adjustment items are specified in table "Adjusting items included in Operating Profit " 3) Treasury shares held by the company not included

Disclosure procedure

This stock exchange release is a summary of Oriola-KD Corporation's Interim Report January-June 2016. The complete report is attached to this release in pdf format and is also available on Oriola-KD's website at www.oriola-kd.com/investors .

Next interim report

Oriola-KD Corporation will publish its results for the third quarter of 2016 on 20 October 2016.Espoo, 18 July 2016

Board of Directors of Oriola-KD Corporation

Further information:

Eero Hautaniemi President and CEO tel. +358 (0)10 429 2109 e-mail: eero.hautaniemi@oriola.com

Sari Aitokallio CFO tel. +358 (0)10 429 2112 e-mail: sari.aitokallio@oriola.com

Distribution: NASDAQ OMX Helsinki Ltd Key media

Released by: Oriola-KD Corporation Corporate Communications Orionintie 5 02200 Espoo www.oriola-kd.com

HUG#2029164

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 110

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Dental Exams Are Routine Until They Catch Something Early

Updated Category News Views 60

A mouth can look perfectly fine right up until it does not. That is the unglamorous value in the dental exam and X-rays visit described by Dr. Eric Runyon of Smiles Unlimited in Belton, Missouri: it is a structured look for trouble before pain, swelling, or a cracked tooth forces the issue. Nobody throws a parade for preventive care, but waiting for symptoms has a habit...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
es